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 Original Article 
 Use of oral anticoagulants in atrial fi brillation is highly 
variable and only weakly associated with estimated 
stroke risk: Cross-sectional population database study 
 Tobias  Dreischulte 1,2 ,  Karen  Barnett 2 ,  Vishnu  Madhok 3  &  Bruce  Guthrie 3 
 1 Tayside Medicines Governance Unit, NHS Tayside, Dundee, UK,  2 University of Edinburgh, Edinburgh, UK, and
 3 University of Dundee, Dundee, UK 
 ABSTRACT 
 Background: Current international guidelines promote the use of stroke risk stratiﬁ cation tools to inform decision making about 
oral anticoagulant (OAC) use in atrial ﬁ brillation (AF). 
 Objectives: To examine (a) diﬀ erences between CHADS 2 and CHA 2 DS 2 VASc in classifying stroke risk in a primary care population 
of AF patients; (b) patterns of use of antithrombotics by stroke risk; and (c) patient and practice characteristics associated with use 
of oral anticoagulants in patients with AF. 
 Methods: Cross-sectional multilevel modelling study of all patients with AF and without rheumatic heart disease or valve 
replacement ( n    21 564) from 315 Scottish General Practices. 
 Results: (a) CHADS 2 characterized 30.3% in the intermediate and 53.8% in the high-risk category, compared to CHA 2 DS 2 VASC only 
9.7% intermediate and 85.1% high-risk. (b) Of included patients, 17.8% were currently not prescribed any antithrombotic and 43.3% 
were on OAC. OAC use was only weakly related to stroke risk. (c) Patients with paroxysmal AF and those with dementia and previ-
ous peptic ulcer (adjusted ORs 0.26, 0.25 and 0.79) were less likely to be prescribed OAC. OAC use varied over ﬁ ve-fold between 
practices after adjustment for patient case mix, with remote and non-training practices and those with high levels of high-risk pre-
scribing being more likely to prescribe OAC. 
 Conclusion: Evidence was found of both underuse and overuse of OAC in patients with AF. Promoting instruments for stroke risk 
assessment in AF is a plausible but untested strategy to improve decision making in AF, and its impact on OAC prescribing and patient 
outcomes should be evaluated in pragmatic trials. 
 Keywords:   atrial ﬁ brillation ,  family practice ,  quality of health care ,  stroke risk ,  antithrombotics 
 INTRODUCTION 
 Atrial ﬁ brillation (AF) is common, aﬀ ecting approxi-
mately 1% of the general population (4.5 million patients 
in the European Union), and its prevalence is estimated 
to at least double in the next 50 years due to aging 
populations (1 – 3). AF is associated with a ﬁ ve-fold 
increase in the risk of stroke (4) and oral anticoagulation 
(OAC) signiﬁ cantly reduces this risk by approximately 
60% in patients of all ages (5). OAC is substantially more 
eﬃ  cacious than aspirin in preventing stroke (by approx-
imately 40%) but approximately doubles the risk of 
intracranial haemorrhage (6). Nevertheless, all-cause 
mortality is signiﬁ cantly reduced (by approximately 
25%) under OAC compared to aspirin treatment, and 
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 KEY MESSAGE: 
·  Use of oral anticoagulants in atrial ﬁ brillation varies substantially between practices and is only weakly associated with 
stroke risk. 
·  Using stroke and bleeding risk stratiﬁ cation tools is a plausible but untested strategy to improve decision making on oral 
anticoagulation in atrial ﬁ brillation, which should be evaluated in pragmatic trials. 
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despite the costs associated with international normal-
ized ratio (INR) monitoring, OAC use has been shown to 
be cost-eﬀ ective in AF patients with additional risk fac-
tors for stroke (7,8). 
 Although major bleeding events are estimated to be 
ﬁ ve-to-eight times less likely than ischaemic strokes 
and there is a clear net beneﬁ t of OAC use in AF (espe-
cially when stroke risk is high), major bleeding events 
may be devastating when they do occur (9). For all 
patients, prescribers, therefore, have to balance the 
risks and beneﬁ ts of OAC and aspirin, and current 
guidelines recommend the use of stroke risk-stratiﬁ ca-
tion schemes, which generally use a three-fold classiﬁ -
cation:  ‘ High-risk ’ patients are generally recommended 
for OACs and  ‘ low-risk ’ patients for aspirin or no anti-
thrombotic treatment, while  ‘ intermediate-risk ’ 
patients are recommended for either OAC or aspirin 
(4,10,11). However, antithrombotic treatment in atrial 
ﬁ brillation is used inconsistently, and particular con-
cern has been raised over underuse of OAC in patients 
with high risk of stroke (12,13). 
 The risk-classiﬁ cation scheme most commonly rec-
ommended in guidelines internationally is the CHADS 2 
score (Box 1) (4,14 – 16), which is also promoted by the 
current (2012/13) version of the United Kingdom (UK) 
Quality and Outcomes framework (QOF) (a system of 
ﬁ nancial incentives oﬀ ered to general practices for their 
achievements against a range of quality indicators 
relating mainly to care for long-term conditions) 
(17). However, CHADS 2 has been criticized not only for 
classifying large proportions of patients into the inter-
mediate risk group where treatment recommendations 
are ambiguous (18,19), but also for misclassifying 
patients as intermediate risk of stroke who are in fact 
low-risk (potentially exposing them unnecessarily to the 
risks and burdens of OACs (20)) or high-risk (potentially 
denying them the beneﬁ ts of OAC (19)). 
 Partly in response, a revised scheme (CHA 2 DS 2 VASc) 
has been developed, which includes additional risk fac-
tors for stroke (Box 1). A merit of CHA 2 DS 2 VASc is that it 
predicts better who is low-risk, and current European 
guidelines, therefore, recommend its use to more clearly 
identify those patients with CHADS 2   1, who are unlikely 
to beneﬁ t from OAC. CHA 2 DS 2 VASc does not, however, 
solve the problem of misclassifying low-risk patients as 
intermediate risk (4,20) and neither scheme is superior 
to the other in terms of its overall predictive ability for 
stroke, which is modest at best (21,22). 
 The aims of this study were (a) to examine diﬀ er-
ences between the CHADS 2 , and CHA 2 DS 2 VASc schemes 
in classifying stroke risk in a population of AF patients, 
(b) to investigate patterns of use of antithrombotic 
treatment by stroke risk, and (c) to identify patient and 
practice characteristics associated with use of oral 
anticoagulants. 
 METHODS 
 Data source 
 Data was extracted from the Primary Care Clinical Infor-
matics Unit (PCCIU) at University of Aberdeen, which 
contains data of registered patient populations from 
315 (31%) of Scottish general practices, that are repre-
sentative of Scotland as a whole in terms of age and 
socio-economic deprivation (23). 
 Study population 
 Patients were eligible for inclusion if they were alive on 
the index date (31 March 2007), permanently registered 
with the practice and had a Quality and Outcomes 
Framework (QOF) deﬁ ned Read Code for atrial ﬁ brilla-
tion or ﬂ utter (24) recorded on or before the index date. 
Patients with a most recently recorded code of 
 ‘ AF resolved ’ were excluded, as were those with a history 
of rheumatic heart disease or valve replacement surgery 
(deﬁ ned using QOF Read Codes where available (24), 
and bespoke code-sets where necessary), to focus atten-
tion on those to whom current guidelines applied. 
 Antithrombotic prescriptions 
 The most recent date of prescription of oral anticoagula-
tion (OAC, deﬁ ned as drugs in British National Formulary 
(BNF) section 2.8.2), and antiplatelet drugs (aspirin, 
clopidogrel or dipyridamole preparations in BNF 
section 2.9) was extracted, as was the date last recorded 
 Box 1. Points scored for stroke risk factors under CHADS 2 (14,43) 
and CHA 2 DS 2 VASc (43). Under both schemes, the scored points are 
summed, with 0    ‘ low risk ’ , 1    ‘ intermediate risk ’ and    2   
‘ high risk ’ . 
No. of points scored under
Risk factor CHADS 2 CHA 2 DS 2 VASc
Congestive heart failure 1 1
Hypertension 1 1
Aged    75 years 1 2
Diabetes mellitus 1 1
Stroke, TIA or thromboembolic 
event
2 2
Vascular disease (prior 
myocardial infarction, 
peripheral arterial disease 
or complex aortic plaque 
on transthoracic 
echocardiogram a )
Not included 1
Aged 65 – 74 years Not included 1
Sex, female Not included 1
 
a Transoesophageal echocardiogram is not a routine investigation in
patients with simple AF in UK primary care, and is not routinely coded 
in primary care records, so not included. 
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for non-prescription aspirin use (as deﬁ ned by QOF)
(24). Current treatment was deﬁ ned as a prescription 
issued in the 12 weeks before the index date, or over the 
counter (OTC) aspirin use recorded in the previous year 
(since QOF incentivises at least annual recording of OTC 
aspirin use). 
 Co-variables 
 At patient level, age, sex, Carstairs deprivation score 
(25), number of active repeat drugs and the presence 
of stroke risk factors (i.e. coronary heart disease, heart 
failure, diabetes, hypertension, peripheral vascular dis-
ease, prior stroke or transient ischaemic attack as 
deﬁ ned by QOF) and relative contraindications for the 
use of antithrombotics, i.e. peptic ulcer (deﬁ ned by rel-
evant Read codes) and dementia (deﬁ ned by relevant 
Read codes or prescription of an acetylcholinesterase 
inhibitor), were considered (26). At practice level, list 
size, urban/rural location, accreditation for postgraduate 
training, dispensing status and contract status (General 
Medical Services or Personal Medical Services con-
tract), and a composite indicator of rates of high-risk 
prescribing were considered (27). The latter comprised 
of 15 validated indicators of hazardous prescribing of 
drugs in clinical situations identiﬁ ed as clearly high 
risk in the British National Formulary, clinical guidelines 
or national safety alerts and commonly implicated in 
drug-related hospital admissions or in drug-related 
death (27,28). 
 Data analysis 
 For analyses examining current treatment, those diag-
nosed less than 12 weeks before the index date were 
excluded, since decisions about antithrombotic treat-
ment in newly diagnosed AF can be prolonged. Stroke 
risk on index date was calculated using the CHADS 2 , and 
CHA 2 DS 2 VASc schemes. Current use and use of OAC ever 
since diagnosis of AF by each scheme were calculated. 
 Multilevel logistic regression was used to examine 
how current OAC treatment was associated with patient 
and practice characteristics, and variation between prac-
tices after accounting for diﬀ erences in patient charac-
teristics. Univariable and adjusted odds ratios were 
calculated for patient and practice variables. Variation 
between practices was examined by estimating residual 
variation at practice level in a model with patient vari-
ables ﬁ tted to account for diﬀ erences in case-mix (29). 
All models were ﬁ tted with second order penalized qua-
si-likelihood estimation, and assumptions of normality of 
level 2 residuals checked graphically. Initial analysis 
was carried out in SPSS v17.0, and multilevel logistic 
regression in MLWin 2.0 (Centre for Multilevel Model-
ling, University of Bristol, UK). 
 RESULTS 
 Study population 
 There were 1 760 223 permanently registered patients 
on the index date, of whom 21 096 (crude prevalence 
1.20%) were recorded as having atrial ﬁ brillation as 
deﬁ ned above. For the analyses relating to current 
treatment, 653 patients diagnosed in the 12 weeks 
before index date were excluded. Table 1 shows the 
demographics of patients without rheumatic heart dis-
ease or valve replacement. AF prevalence rose steeply 
with age, comorbidity was common and the median 
number of oral repeat drugs co-prescribed with any 
anticoagulant was ﬁ ve. 
 Diﬀ erences between risk stratiﬁ cation schemes 
 Table 2 shows classiﬁ cation of stroke risk for the two 
schemes. CHADS 2 characterizes almost a third of patients 
(30.3%) in the intermediate-risk category. In contrast, 
and by design, CHA 2 DS 2 VASC classiﬁ es only 9.7% as 
intermediate-risk but most patients (85.1%) as high-risk 
(31.3% more than CHADS 2 ). 
 Antithrombotic treatment by stroke risk 
 A total of 17.8% patients were not prescribed any anti-
thrombotic treatment, 38.9% were only prescribed anti-
platelets, 39.1% only OAC, and 4.3% OAC plus an 
antiplatelet (Table 3). Overall, therefore, 43.3% of 
 Table 1. Demographics of 21 096 patients with atrial ﬁ brillation without 
rheumatic heart disease or valve replacement. 
Basic demographics
Male 54.6%
Mean age in years (95% CI) 75.5 (75.3 – 75.6)
Prevalence of atrial ﬁ brillation by age 
group (95% CI)
45 – 54 years 0.3% (0.2 to 0.3)
55 – 64 years 1.1% (1.0 – 1.1)
65 – 74 years 3.5% (3.4 – 3.6)
75 – 84 years 7.8% (7.7 – 8.0)
85 years and over 12.2% (11.9 – 12.6)
Prevalence of comorbidity in patients with 
atrial ﬁ brillation
Hypertension 54.7% (54.0 – 55.3)
Coronary heart disease 38.6% (37.9 – 39.2)
Heart failure 20.6% (20.0 – 21.1)
Diabetes 16.5% (16.0 – 17.0)
Non-haemorrhagic stroke or TIA 13.5% (13.0 – 14.0)
Peripheral vascular disease 6.6% (6.3 – 7.0)
Dementia 4.9% (4.6 – 5.2)
Previous peptic ulcer 10.0% (9.6 – 10.4)
No. of oral repeat drugs in addition to an oral 
anticoagulant
Mean (95% CI) 5.6 (5.55 – 5.63)
Median (Interquartile range) 5 (2 – 7)
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to ﬁ ve drugs were most likely to be prescribed OAC, 
while those on more drugs were progressively less likely 
to (35.7% in those on 12 or more drugs versus 49.0% in 
those on three to ﬁ ve drugs, adjusted OR: 0.55, 95%CI: 
0.45 – 0.66). Weaker associations were found for gender 
and comorbidity (Table 3). 
 Patients registered with more remote and non-
training practices were more likely to be anticoagu-
lated in both univariable and adjusted analyses as 
were those in practices with the highest rates of  ‘ high-
risk prescribing ’ (27). At practice-level, a median of 
44.4% (interquartile range: 37.8 – 52.0) of patients were 
currently anticoagulated. After adjustment for patient-
level characteristics in the multilevel model, the odds 
of an individual receiving OAC varied from 0.39 (95%CI: 
0.30 – 0.51) in the practice with lowest use to 2.13 
(95%CI: 1.35 – 3.36) in the practice with highest use; 20 
(6.3%) practices had signiﬁ cantly higher than average, 
and 25 (7.9%) signiﬁ cantly lower than average OAC use 
(Figure 1). 
 DISCUSSION 
 Main ﬁ ndings 
 In this study, the CHADS 2 classiﬁ cation scheme classiﬁ ed 
almost two thirds of patients into the intermediate 
stroke risk category. In comparison, CHAD 2 VA 2 Sc classi-
ﬁ es many fewer patients in the intermediate but many 
more in the higher risk category than CHADS 2 . OAC use 
was only weakly associated with risk estimated by both 
schemes and there was signiﬁ cant evidence of likely 
under-treatment. Only 43% of all patients with AF were 
currently anticoagulated (although 59% of all patients 
had received OAC at some point since AF diagnosis). 
Moreover, 3633 (18%) of all patients were receiving 
patients were current OAC users, although 58.5% had 
used OAC at some point since diagnosis of AF. For both 
risk stratiﬁ cation schemes, fewer patients were on no 
treatment as risk increased, but current OAC use was 
similar in high and intermediate-risk groups (42 – 44%) 
and only marginally higher than in low-risk groups 
(CHADS 2 35.2%; CHA 2 DS 2 VASc 28.6%). 
 Patient and practice characteristics associated 
with current OAC treatment 
 Table 4 shows how receipt of current OAC varies by 
patient and practice characteristics. Among the patient-
level variables investigated, age, AF type, and relative 
contraindications showed the strongest associations 
with current anticoagulant use in multivariate analyses. 
Patients aged 65 – 74 years were more likely to be cur-
rently prescribed OAC, while younger and older patients 
were progressively less likely to (34% of patients aged 85 
or older versus 52.2% of 65 – 74 year olds, adjusted OR: 
0.33, 95%CI: 0.30 – 0.36). Patients with paroxysmal AF 
were much less likely to be anticoagulated than those 
with chronic AF (20.0% versus 46.7%, adjusted OR: 0.26, 
95%CI: 0.23 – 0.29), as were those with dementia and (to 
a lesser extent) those with previous peptic ulcer. Strong 
associations were also found between current OAC use 
and the number of drugs prescribed. Patients on three 
 Table 3. Current treatment and ever anticoagulation by risk stratiﬁ cation for 20 443 patients with atrial ﬁ brillation without rheumatic heart disease 
or valve replacement, and diagnosed for at least 12 weeks. 
All patients  ‘ Low risk ’ as deﬁ ned by
 ‘ Intermediate risk ’ 
as deﬁ ned by  ‘ High risk ’ as deﬁ ned by
 n (%) CHADS 2 CHA 2 DS 2 VASc CHADS 2 CHA 2 DS 2 VASc CHADS 2 CHA 2 DS 2 VASc
 n    20 443  n    3218  n    1061  n    6163  n    1955  n    11 062  n    17 427
No current antithrombotic 
treatment
17.8% 27.0% 39.4% 17.5% 23.4% 15.2% 15.8%
Current antiplatelet only a 38.9% 34.5% 30.0% 39.4% 34.3% 39.9% 39.9%
Current anticoagulant only b 39.1% 35.2% 28.6% 38.3% 38.2% 39.7% 39.2%
Current anticoagulant plus 
antiplatelet c 
4.3% 3.3% 2.1% 4.8% 4.1% 5.2% 5.0%
All current anticoagulant d 43.3% 38.5% 30.6% 43.1% 42.3% 44.9% 44.2%
Anticoagulant ever since diagnosis 58.5% 53.0% 48.4% 57.4% 57.7% 60.8% 59.2%
 
a 31.9% on aspirin only, 4.2% on dipyridamole or clopidogrel only, 2.8% on aspirin and (clopidogrel or dipyridamole) and 0.02% on all three 
antiplatelets. 
 b 0.5% additionally prescribed an antiplatelet drug other than aspirin. 
 c 0.2% additionally prescribed an antiplatelet drug other than aspirin. 
 d 0.3% prescribed an oral anticoagulant other than warfarin. 
 Table 2. Predicted risk category for 21 096 patients with atrial ﬁ brillation 
without rheumatic heart disease or valve replacement. 
Low risk
 n (%)
Intermediate risk
 n (%)
High risk
 n (%)
CHADS 2 3358 (15.9) 6396 (30.3) 11 342 (53.8)
CHA 2 DS 2 VASc 1109 (5.3) 2039 (9.7) 17 948 (85.1)
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 Table 4. Patient and practice variables associated with current prescription of anticoagulation for 20 443 patients with atrial ﬁ brillation without 
rheumatic heart disease or valve replacement, and diagnosed for at least 12 weeks. Univariable and adjusted odds ratios are estimated in a multilevel 
model to account for clustering by practice. Adjustment was by variables shown in the table. 
Variable a 
No. (%) of patients currently 
anticoagulated
Multilevel univariable 
odds ratio (95% CI)
Multilevel adjusted 
odds ratio (95% CI) b 
Patient level variables
Age
   45 years ( n    273) c 51 (18.7) 0.21 (0.15 – 0.28) 0.26 (0.19 – 0.36)
45 – 54 years ( n    640) c 204 (31.9) 0.43 (0.36 – 0.51) 0.50 (0.41 – 0.60)
55 – 64 years ( n    2282) c 1001 (43.9) 0.70 (0.63 – 0.77) 0.70 (0.63 – 0.78)
65 – 74 years ( n    5265) c 2750 (52.2) 1 1
75 – 84 years ( n    7573) c 3647 (48.2) 0.85 (0.79 – 0.91) 0.83 (0.77 – 0.89)
85   years ( n    4410) c 1208 (27.4) 0.34 (0.32 – 0.38) 0.33 (0.30 – 0.36)
Gender
Male ( n    11 170) 5179 (46.4) 1 1
Female ( n    9273) 3682 (39.7) 0.76 (0.72 – 0.81) 0.90 (0.85 – 0.96)
Co-medication
No. of repeat oral drugs 1464 (37.6) 1 1
excluding anticoagulants
0 – 2 drugs ( n    3892)
3 – 5 drugs ( n    7804) 3826 (49.0) 1.53 (1.41 – 1.66) 1.33 (1.21 – 1.45)
6 – 8 drugs ( n    5899) 2519 (42.7) 1.17 (1.08 – 1.28) 0.93 (0.84 – 1.02)
9 – 11 drugs ( n    2161) 807 (37.3) 0.93 (0.83 – 1.04) 0.67 (0.59 – 0.76)
12   drugs ( n    687) 245 (35.7) 0.86 (0.72 – 1.02) 0.55 (0.45 – 0.66)
AF type
Chronic AF ( n    17 886) 8349 (46.7) 1 1
Paroxysmal AF ( n    2557) 512 (20.0) 0.27 (0.24 – 0.30) 0.26 (0.23 – 0.29)
Comorbidity
No diabetes ( n    17 050) 7263 (42.6) 1 1
Diabetes ( n    3393) 1598 (47.1) 1.19 (1.11 – 1.28) 1.18 (1.08 – 1.28)
No heart failure ( n    16 194) 6788 (41.9) 1 1
Heart failure ( n    4249) 2073 (48.8) 1.36 (1.27 – 1.45) 1.45 (1.35 – 1.57)
No hypertension ( n    9240) 3763 (40.7) 1 1
Hypertension ( n    11 203) 5098 (45.5) 1.23 (1.16 – 1.30) 1.19 (1.11 – 1.27)
No stroke/TIA ( n    17 863) 7509 (42.5) 1 1
Stroke/TIA ( n    2760) 1352 (49.0) 1.33 (1.24 – 1.42) 1.48 (1.35 – 1.62)
No PVD ( n    19 069) 8295 (43.5) 1 1
PVD ( n    1374) 566 (41.2) 0.94 (0.84 – 1.05) 0.88 (0.78 – 0.99)
Relative contra-indications
No dementia ( n    19 437) d 8717 (44.8) 1 1
Dementia ( n    1006) d 144 (14.3) 0.21 (0.17 – 0.25) 0.25 (0.20 – 0.30)
No history PU ( n    18 384) 8065 (43.9) 1 1
History PU ( n    2059) 796 (38.7) 0.82 (0.75 – 0.91) 0.79 (0.72 – 0.88)
Practice level variables
Training status
Not training ( n    10 929) a 4913 (45.0) 1 1
Training ( n    9218) 3801 (41.2) 0.86 (0.77 – 0.96) 0.87 (0.78 – 0.97)
Rurality
Primary city ( n    6955) 2830 (40.7) 1 1
Urban area ( n    6980) 2992 (42.9) 1.09 (0.96 – 1.24) 1.07 (0.94 – 1.23)
Accessible ( n    3322) 1534 (46.2) 1.29 (1.11 – 1.48) 1.20 (1.03 – 1.40)
Remote ( n    1479) 677 (45.8) 1.21 (1.11 – 1.48) 1.13 (0.89 – 1.43)
Very remote ( n    1707) 828 (48.5) 1.40 (1.17 – 1.69) 1.44 (1.19 – 1.74)
High risk prescribing rate
Quartile 1 low ( n    6187) 2508 (40.5) 1 1
Quartile 2 ( n    5301) 2276 (42.9) 1.05 (0.92 – 1.20) 1.01 (0.87 – 1.17)
Quartile 3 ( n    4896) 2160 (44.1) 1.10 (0.96 – 1.27) 1.05 (0.90 – 1.23)
Quartile 4 high ( n    4059) 1917 (47.2) 1.29 (1.12 – 1.49) 1.25 (1.07 – 1.45)
 a Adjusted for the confounders shown in the table. Other variables examined but not signiﬁ cantly associated in adjusted model were socioeconomic 
deprivation (based on the postcode sector of the patient ’ s address (25)), duration of atrial ﬁ brillation, presence of coronary heart disease, practice 
list size, whether the practice held a standard General Medical Services or a locally varied Personal Medical Services contract, whether the practice 
dispensed its own prescriptions. AF: atrial ﬁ brillation; TIA: transient ischemic attack; PVD: peripheral vascular disease; PU: peptic ulcer. 
 b Practice level data missing for 6 practices and 296 patients. 
 c Age in years assessed on 31 March 2007. 
 d Dementia (deﬁ ned as either a relevant Read code or prescription of an acetylcholinesterase inhibiting drug that is exclusively used in dementia (26). 
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that the study used data for a population of patients that 
is representative of Scotland in terms of age and socio-
economic deprivation (23), and some factors support the 
accuracy of the dataset used in this study. In the UK 
National Health Service, patients register with one gen-
eral practice, which functions as the gatekeeper and 
(although specialists may advise initiation of chronic 
drug treatment) GPs are responsible for prescribing OAC 
and antiplatelets. In addition, all examined morbidities 
and prescribing are included in QOF, which incentivises 
accurate documentation. Nevertheless, several factors 
that have been shown to inﬂ uence prescribers ’ decision 
making (33) could not be accounted for here due to 
inconsistent documentation, including alcohol consump-
tion, increased falls risk, patients ’ ability to comply with 
OAC treatment and patient preference. 
 Comparison with existing literature 
 The ﬁ nding that in this Scottish population, CHADS 2 clas-
siﬁ ed a relatively large number of patients with AF 
(30.3%) in the intermediate-risk category is a deliberate 
consequence of CHAD 2 VA 2 Sc placing a focus on identify-
ing a small number of patients who do not need to be 
anticoagulated (22) and consistent with the ﬁ ndings of a 
recent population-based study conducted in the UK (13). 
Our ﬁ ndings also conﬁ rm recent studies reporting sub-
optimal ( ~ 50%) uptake of OAC in high-risk patients 
neither antiplatelets nor OAC, including many at 
high-risk of stroke. The study also found some evidence 
of potential overtreatment in terms of OAC use in 
patients classiﬁ ed at low-risk of stroke, although this 
was less common than under-treatment. In addition, 
873 (5%) of all patients were co-prescribed OAC and 
antiplatelets (for which there is only a narrow indication 
in AF patients within the ﬁ rst year after acute coronary 
syndrome (30 – 32)). Use of OAC was only weakly associ-
ated with known risk factors for stroke in AF (such as 
previous stroke or TIA, heart failure, and hypertension) 
and was much less commonly prescribed to older 
patients (where the net-beneﬁ t of OAC use is highest 
(4)). OAC use was also much lower in patients with par-
oxysmal AF, in those on many other drugs and those 
with relative contraindications . 
 After adjustment for patient characteristics, OAC 
uptake varied more than ﬁ ve-fold between practices, 
with patients in more remote practices, non-training 
practices and those with high levels of high-risk prescrib-
ing being more likely to be prescribed OAC. 
 Strengths and limitations of the study 
 As with all observational studies using routine clinical 
data, the ﬁ ndings are potentially subject to residual con-
founding due to unmeasured confounders, and inconsis-
tencies in the recording of data. However, a strength is 
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 Figure 1. Variation between practices in receipt of OAC by individual patients (odds ratio and 95% conﬁ dence intervals) after adjustment for patient 
characteristics. An odds ratio of 1.00 represents the average across all 315 practices. 
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given that clinical trials (even those with broad eligibility 
criteria) underestimate bleeding risk from OAC use in 
clinical practice (37) and that many patients prefer not 
to take OAC, bleeding risk and patient preference are 
likely to remain important drivers for decision making in 
AF (32). Newer OAC, which do not require regular INR 
monitoring, may make OAC use more acceptable to 
patients and might be safer, but limited trial evidence in 
patients at intermediate risk of stroke and high treat-
ment costs are likely to limit their use in many countries 
in the foreseeable future (38,39). To enable clinicians 
and patients to better balance stroke and bleeding risk, 
a number of bleeding risk assessment tools have been 
developed (40,41), but their utility in practice is limited 
by the clinical dilemma that many risk factors for stroke 
and major haemorrhage overlap (42). 
 In summary, therefore, promoting the uptake of cur-
rent stroke risk stratiﬁ cation schemes (alone or in com-
bination with current bleeding risk assessment 
instruments) is a plausible but untested strategy to 
improve decision making in AF. 
 Conclusion 
 Treatment with OAC and aspirin was largely unrelated 
to stroke risk estimated by both risk-stratiﬁ cation 
schemes examined, with considerable evidence of under-
treatment, and some evidence of over-treatment. The 
poor alignment of prescribing practices with current 
stroke risk assessment tools may in part be explained by 
the limited use of these tools in clinical practice or by 
(perceived or actual) barriers to managing treatment 
with OAC, but may also be due to inherent limitations of 
existing instruments. Although potential beneﬁ ts of 
using risk-stratiﬁ cation schemes seem plausible, the 
impact of such schemes on uptake of OAC or patient-
centred outcomes can, therefore, not be assumed and 
should be evaluated in pragmatic trials. 
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(12,13), a lower tendency to use OAC in patients with 
relative contraindications (13) and in those with parox-
ysmal AF (34,35). 
 The ﬁ nding that 59% of all patients had received OAC 
at some point since AF diagnosis but only 43% were cur-
rent OAC users is also consistent with previous estimates 
that over a quarter of patients with AF commencing OAC 
do not take it long term (35). A new ﬁ nding of our study 
is the substantial variation between practices in their 
tendency to prescribe OAC. While the reasons for this 
variation require further investigation, a possible expla-
nation is that remoteness, non-training status and higher 
levels of high-risk prescribing are in fact proxies for a 
lesser awareness or higher tolerance of medication 
safety risks. 
 Implications for clinical practice and future research 
 In this study, OAC use was only weakly associated with 
risk estimated by both schemes suggesting that risk 
stratiﬁ cation is not routinely used in decision making and 
many patients at high risk of stroke were found to have 
never been treated with OAC. In addition, there appears 
to be a misconception by prescribers that stroke risk is 
lower in paroxysmal than in chronic AF (OAC use in 
patients with paroxysmal AF was much lower) (4), and 
there was considerable variation in OAC use between 
practices. All of these ﬁ ndings make it very likely that 
OAC use in primary care could be increased. 
 In the UK, general practitioners are now ﬁ nancially 
rewarded both for documenting CHADS 2 assessment 
and for using OAC in up to 70% of AF patients with 
CHADS 2    2 (17) and support software has been devel-
oped and implemented in practices ’ electronic medical 
records (EMRs), which can ﬂ ag up patients with a CHADS 2 
score of two not receiving warfarin (36). While these 
strategies may help to increase the use of stroke risk 
stratiﬁ cation tools in clinical practice, it remains to be 
seen whether they will increase OAC prescribing in 
patients with AF. This is partly because almost one third 
of patients with AF were classiﬁ ed by CHADS 2 as inter-
mediate-risk, where aspirin may be perceived as a legit-
imate and less burdensome alternative to OAC. Using 
CHA 2 DS 2 VASc in line with current ESC guidance has the 
advantage of prompting prescribers to consider OAC as 
the preferred choice in virtually all AF patients (94.8% of 
patients in this study had a CHA 2 DS 2 VASc    1), but lower 
rates of OAC use in the elderly, in patients on many other 
drugs or with relative contraindications suggest that pre-
scribers may place greater weight on concerns about 
adverse events than estimated stroke risk, which is not 
always irrational. Many patients who are classiﬁ ed as 
high-risk by CHA 2 DS 2 VASc have individual stroke risk 
below that where OAC is clearly beneﬁ cial (20), although 
in most AF patients, the estimated beneﬁ t of OAC out-
weighs any excess risk of bleeding (4,32). In addition, 
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